Clinical trial NCT04228692: Percutaneous Posterior Tibial Nerve Stimulation in Post-operative Voiding Dysfunction After Deep Endometriosis Surgery
Official title: Evaluation of the Benefits of Percutaneous Posterior Tibial Nerve Stimulation in Post-operative Voiding Dysfunction After Deep Endometriosis Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Endometriosis
Dysuria
Keywords: deep endometriosis surgery
voiding dysfunction
self-catheterization
posterior tibial nerve stimulation
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2020-01-14
Enrollment: 4
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Symptomatic endometriosis can be responsible for urinary problems as well as symptoms of clinical bladder hyperactivity and/or symptoms of bladder pain before or during miction that can persist after bladder voiding. Whereas urinary problems can predate surgery due to the endometrial lesions themselves, the surgery can also have functional consequences for urinary function, specifically when there is trauma (incisions, per-operative coagulation) to the inferior hypogastric nerve fibers and/or to the hypogastric plexus.

The incidence of post-surgery urinary symptoms could be as high as 30%. The incidence of voiding problems and specifically of non-obstructive voiding dysfunction can be observed in 17,5% of cases of patients 1-month post-surgery for deep colorectal endometriosis, and persists in 4,8% of women after 12 months.

The gold standard for treatment of voiding problems consists of self-catheterization, as is the case for all non-obstructive voiding dysfunction symptoms. This procedure considerably impacts quality of life. The proper and complete voiding of the bladder remains essential in order to avoid recurring urinary tract infections and pelvic static disorder.

In the case of persistent dysuria, the use of self-catheterization is necessary in 21% of patients after surgery for deep endometriosis, for an average duration of 85 days. To date, few studies have explored the management of post-operative urinary complications after surgery for deep endometriosis. Pharmaceutical alternatives (alpha-blockers, anticholinergics, benzodiazepines) have not proven effective and sometimes cause side effects. However promising alternative treatments are being developed, specifically the neuromodulation of the sacral root. This procedure has been shown effective in the treatment of non-obstructive voiding dysfunction; however, it remains an invasive treatment that has its load of complications and undesirable side-effects. A recent study reports favorable results for the use of sacral neuromodulation in the case of persistent incomplete voiding following surgery for deep colorectal endometriosis. Some studies have also suggested that percutaneous posterior tibial nerve stimulation (PTN) could also be a treatment alternative. The advantage of this procedure is that it is non-invasive and less constraining. No study has yet evaluated whether PTN could also be used to treat patients with persistent voiding dysfunction following surgery for deep endometriosis.

Our study, conducted in the gynecologic department of Croix ROUSSE Hospital, Lyon (France), evaluates PTN as a new treatment option for post-operative voiding dysfunction in women who suffer from deep endometriosis. Our aim is to prove that the use of PTN can reduce the duration of self-catheterization by 50% when compared to self-catheterization only.


Eligibility criteria: Inclusion Criteria:

* Patients who are eligible for the French public healthcare system
* Patients who have given their consent for this research

Exclusion Criteria:

* Patients with cognitive, psychiatric or motor disturbances, that do not allow for independent use of the device
* Patients who do not speak French
* Patients who have had a surgery (bladder or ureters) for endometriosis or any other reason.
* Patients who were participating in another ongoing study, or within the exclusion time stipulated by another study (at the discretion of the investigator)
* Patients unable to give their consent (protected by law: under guardianship / trusteeship)
* Patients who are taking a pharmaceutical treatment for urological problem (anticholinergics, alpha-blockers, prostaglandin)
* Pregnant or breastfeeding women
* Patients with a pacemaker
* Patients with dermatological problem in the area where the device's electrodes have to be installed

Primary outcomes:
measure: Reduction of 50% of total duration of self-catheterization in the self-catheterization + PTN group
timeFrame: From the day of surgery to the end of self-catheterization or until a maximum of 3 months
Secondary outcomes:
measure: Number of self-catheterizations per day
timeFrame: From the day of surgery to the end of self-catheterization or until a maximum of 3 months
measure: Post voiding residual urine volume (PVR)
timeFrame: From the day of surgery to the end of self-catheterization or until a maximum of 3 months
measure: number of PVR> 50% of spontaneous miction
timeFrame: From the day of surgery to the end of self-catheterization or until a maximum of 3 months
measure: side effects of PTN
timeFrame: From the day of surgery to the end of self-catheterization or until a maximum of 3 months
measure: number of sessions of PTN per week
timeFrame: From the day of surgery to the end of self-catheterization or until a maximum of 3 months
measure: duration of each session of PTN
timeFrame: From the day of surgery to the end of self-catheterization or until a maximum of 3 months
Other outcomes:
Locations:
city: Lyon
country: France
facility: Hôpital de la Croix Rousse
Study officials:
affiliation: Hospices Civils de Lyon
name: Sophie WAREMBOURG, Dr
role: PRINCIPAL_INVESTIGATOR
References: